NCT07388758 2026-02-05
Scipibaimab Combined With Tislelizumab in Patients With First-Line Treatment-Failed Recurrent/Metastatic Nasopharyngeal Carcinoma
Sun Yat-sen University
Phase 2 Not yet recruiting
Clinical Trials
9 trialsNCT07331428 2026-01-09
MRG003 Induction and Capecitabine Maintenance With PD-1 in Locally Recurrent NPC
Fujian Cancer Hospital
Phase 2 Not yet recruiting
NCT06781112 2025-01-17
A Phase II Study of TPF With PD-1 Inhibitor Induction Therapy for Locally Advanced Nasopharyngeal Carcinoma
Chengdu University of Traditional Chinese Medicine
Phase 2 Not yet recruiting
NCT06383780 2024-07-16
Tislelizumab in Combination With GP or TPC Regimen for the Treatment of Nasopharyngeal Carcinoma With Bone Metastasis.
Sun Yat-sen University
Phase 3 Recruiting
NCT05211232 2024-04-18
Neoadjuvant and Adjuvant Tislelizumab for Nasopharyngeal Carcinoma
Sun Yat-sen University
Phase 3 Active not recruiting
NCT06331845 2024-03-26
Stop and go Strategy as First-line Treatment for Widely Metastatic Nasopharyngeal Carcinoma
Fujian Cancer Hospital
Phase 2 Not yet recruiting
NCT05448885 2022-07-08
Neoadjuvant and Adjuvant Tislelizumab for Nasopharyngeal Carcinoma
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Unknown
NCT05342792 2022-04-25
Metronomic Capecitabine With or Without PD-1 Antibody as Adjuvant Therapy in High-risk Nasopharyngeal Carcinoma
Sun Yat-sen University
Phase 3 Recruiting
NCT04921995 2022-04-04
RETICULA-NPC
Fudan University
Phase 2 Unknown